University of California San Francisco
Give to UCSF
But what is uncertainty? What’s going on in the brain when we feel uncertain? And how might long-term uncertainty experienced by an entire population affect community health?
Lisa had a rare mutation that meant she was not able to combine two words until she was 3, and she didn’t take part in imaginative play until she was 10. Could a drug for MS be repurposed to help her?
Now in their seventh year, the Best Global Universities rankings focus on schools’ academic research and reputation overall instead of specific undergraduate and graduate programs. These global rankings help the increasing number of students exploring international higher education options to more accurately compare institutions around the world.
UCSF researchers are finding new clues to how neuropsychiatric disorders unfold by focusing on the role of a little-studied form of DNA in early brain development.
A cellular therapy for epilepsy developed at UCSF has been employed for the first time in a sea lion with intractable seizures caused by ingesting toxins from algal blooms.
Older adults who took weekly 15-minute “awe walks” for eight weeks reported increased positive emotions and less distress in their daily lives.
The achievement of “plug and play” performance demonstrates the value of so-called ECoG electrode arrays for BCI applications.
Though FTD is not as well known as Alzheimer’s disease, it’s the second most common cause of dementia in people under 65, and there’s currently no treatment.
New UCSF research sheds light on how immune system B cells that infiltrate the central nervous system may drive multiple sclerosis.
UCSF scientists now have evidence from research that women with Alzheimer’s live longer than men with the disease because they have genetic protection from the ravages of the disease.
New research by neuroscientists at the University of Pittsburgh and UC San Francisco revealed that a simple, earbud-like device developed at UCSF that imperceptibly stimulates a key nerve leading to the brain could significantly improve the wearer’s ability to learn the sounds of a new language.
A newly completed phase 3, multicenter clinical trial has found that an immune-modulating drug can silence inflammatory disease activity in a large majority of patients with relapsing multiple sclerosis (RMS) – the most common form of the illness, in which symptoms wax and wane.
